Gastroenteropancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-02-18Clinical Trial Update: Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours [Phase 3]
Phase 3 trial of lanreotide Autogel in non-functioning gastroenteropancreatic neuroendocrine tumors has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2015-01-22Clinical Trial Update: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract. [Phase 2]
Phase 2 study evaluating Avastin (bevacizumab) with chemotherapy in gastroenteropancreatic neuroendocrine tumors; the trial is completed and…
-
FDA approval · 2014-12-22FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2012-09-12FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves a supplemental application for octreotide acetate (ANDA) by Hikma Pharmaceuticals USA Inc. The approval updates the labeling or…
-
FDA approval · 2009-03-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for octreotide acetate submitted by Hikma Pharmaceuticals USA Inc., under the ANDA pathway.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.